339 related articles for article (PubMed ID: 32486536)
21. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
22. Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation?
Samartzis EP; Samartzis N; Noske A; Fedier A; Caduff R; Dedes KJ; Fink D; Imesch P
Mod Pathol; 2012 Jun; 25(6):885-92. PubMed ID: 22301703
[TBL] [Abstract][Full Text] [Related]
23. PAX2, PAX8 and CDX2 Expression in Metastatic Mucinous, Primary Ovarian Mucinous and Seromucinous Tumors and Review of the Literature.
Ates Ozdemir D; Usubutun A
Pathol Oncol Res; 2016 Jul; 22(3):593-9. PubMed ID: 26797858
[TBL] [Abstract][Full Text] [Related]
24. Seromucinous borderline tumor of the testis-A case report.
Scholz B; Beckert M; Mordstein V; Hohmann N; Walther R; Papadopoulos T
Hum Pathol; 2017 Feb; 60():188-191. PubMed ID: 27597522
[TBL] [Abstract][Full Text] [Related]
25. Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8
Heinze K; Nazeran TM; Lee S; Krämer P; Cairns ES; Chiu DS; Leung SC; Kang EY; Meagher NS; Kennedy CJ; Boros J; Kommoss F; Vollert HW; Heitz F; du Bois A; Harter P; Grube M; Kraemer B; Staebler A; Kommoss FK; Heublein S; Sinn HP; Singh N; Laslavic A; Elishaev E; Olawaiye A; Moysich K; Modugno F; Sharma R; Brand AH; Harnett PR; DeFazio A; Fortner RT; Lubinski J; Lener M; Tołoczko-Grabarek A; Cybulski C; Gronwald H; Gronwald J; Coulson P; El-Bahrawy MA; Jones ME; Schoemaker MJ; Swerdlow AJ; Gorringe KL; Campbell I; Cook L; Gayther SA; Carney ME; Shvetsov YB; Hernandez BY; Wilkens LR; Goodman MT; Mateoiu C; Linder A; Sundfeldt K; Kelemen LE; Gentry-Maharaj A; Widschwendter M; Menon U; Bolton KL; Alsop J; Shah M; Jimenez-Linan M; Pharoah PD; Brenton JD; Cushing-Haugen KL; Harris HR; Doherty JA; Gilks B; Ghatage P; Huntsman DG; Nelson GS; Tinker AV; Lee CH; Goode EL; Nelson BH; Ramus SJ; Kommoss S; Talhouk A; Köbel M; Anglesio MS
J Pathol; 2022 Apr; 256(4):388-401. PubMed ID: 34897700
[TBL] [Abstract][Full Text] [Related]
26. Ovarian Clear Cell Tumors Associated With Seromucinous Borderline Tumor: A Case Series.
Vroobel KM; McCluggage WG
Int J Gynecol Pathol; 2022 Jan; 41(1):76-81. PubMed ID: 33741765
[TBL] [Abstract][Full Text] [Related]
27. Ovarian atypical proliferative (borderline) mucinous tumors: gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive.
Vang R; Gown AM; Barry TS; Wheeler DT; Ronnett BM
Int J Gynecol Pathol; 2006 Jan; 25(1):83-9. PubMed ID: 16306790
[TBL] [Abstract][Full Text] [Related]
28. Endocervical-like (Müllerian) mucinous borderline tumours of the ovary are frequently associated with the KRAS mutation.
Kim KR; Choi J; Hwang JE; Baik YA; Shim JY; Kim YM; Robboy SJ
Histopathology; 2010 Oct; 57(4):587-96. PubMed ID: 20955384
[TBL] [Abstract][Full Text] [Related]
29. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma.
Rekhi B; Deodhar KK; Menon S; Maheshwari A; Bajpai J; Ghosh J; Shylasree ST; Gupta S
APMIS; 2018 Jan; 126(1):45-55. PubMed ID: 29266433
[TBL] [Abstract][Full Text] [Related]
30. Expression and significance of ARID1A mRNA in endometriosis- associated ovarian cancer.
Wang Q; Wang L; L Y; Ding X; Liu A
J BUON; 2017; 22(5):1314-1321. PubMed ID: 29135119
[TBL] [Abstract][Full Text] [Related]
31. Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic study of 109 cases.
Bostwick DG; Tazelaar HD; Ballon SC; Hendrickson MR; Kempson RL
Cancer; 1986 Nov; 58(9):2052-65. PubMed ID: 3756820
[TBL] [Abstract][Full Text] [Related]
32. High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature.
Hatano Y; Tamada M; Asano N; Hayasaki Y; Tomita H; Morishige KI; Hara A
Diagn Pathol; 2019 Jan; 14(1):4. PubMed ID: 30636633
[TBL] [Abstract][Full Text] [Related]
33. Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression.
Choi JY; Han HH; Kim YT; Lee JH; Kim BG; Kang S; Cho NH
Yonsei Med J; 2017 Jan; 58(1):59-66. PubMed ID: 27873496
[TBL] [Abstract][Full Text] [Related]
34. Anaplastic carcinoma in ovarian seromucinous cystic tumor of borderline malignancy.
Okumura T; Muronosono E; Tsubuku M; Terao Y; Takeda S; Maruyama M
J Ovarian Res; 2018 Sep; 11(1):77. PubMed ID: 30176911
[TBL] [Abstract][Full Text] [Related]
35. Ovarian Seromucinous Tumors: Pathogenesis, Morphologic Spectrum, and Clinical Issues.
Nagamine M; Mikami Y
Diagnostics (Basel); 2020 Jan; 10(2):. PubMed ID: 32023964
[TBL] [Abstract][Full Text] [Related]
36. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
Wiegand KC; Hennessy BT; Leung S; Wang Y; Ju Z; McGahren M; Kalloger SE; Finlayson S; Stemke-Hale K; Lu Y; Zhang F; Anglesio MS; Gilks B; Mills GB; Huntsman DG; Carey MS
BMC Cancer; 2014 Feb; 14():120. PubMed ID: 24559118
[TBL] [Abstract][Full Text] [Related]
37. [Mucinous ovarian neoplasms. Prognostically mostly excellent, infrequently a wolf in sheep's clothing].
Lax S; Staebler A
Pathologe; 2014 Jul; 35(4):327-35. PubMed ID: 24962632
[TBL] [Abstract][Full Text] [Related]
38. Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas.
Rodríguez IM; Prat J
Am J Surg Pathol; 2002 Feb; 26(2):139-52. PubMed ID: 11812936
[TBL] [Abstract][Full Text] [Related]
39. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas.
Wiegand KC; Lee AF; Al-Agha OM; Chow C; Kalloger SE; Scott DW; Steidl C; Wiseman SM; Gascoyne RD; Gilks B; Huntsman DG
J Pathol; 2011 Jul; 224(3):328-33. PubMed ID: 21590771
[TBL] [Abstract][Full Text] [Related]
40. MDM2 Expression in Serous and Mucinous Epithelial Tumours of the Ovary.
Abdelaal SE; Habib FM; El Din AA; Gabal SM; Hassan NS; Ibrahim NA
Asian Pac J Cancer Prev; 2016; 17(7):3295-300. PubMed ID: 27509966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]